Latest Entitlement Offer News

Eagle Mountain Mining has issued nearly 120 million new shares and 40 million options, raising just over $1 million, but a significant shortfall remains to be placed. The company aims to secure additional funding to advance its Arizona copper-gold projects.

APC Minerals Limited has raised $264,000 through a discounted top-up placement of 66 million shares, enhancing its financial capacity to pursue new and existing projects.

APC Minerals Limited has successfully closed its pro-rata renounceable entitlement offer, raising $1.38 million despite strong investor demand that exceeded the offer size by over 50%.

Eagle Mountain Mining has closed its entitlement offer, raising just over half of its targeted $1.98 million, with a significant shortfall to be placed alongside lead managers. The funds will support its copper-gold exploration projects in Arizona.

Memphasys Limited has completed a $579K shortfall placement, boosting total funds raised to over $1.12 million to support the commercial rollout of its Felix™ System following recent regulatory approvals.

Vulcan Energy Resources has successfully closed its retail entitlement offer, raising €147 million and increasing HOCHTIEF's ownership to over 15%, eliminating the need for a conditional placement.

Big River Industries has successfully completed a $10 million entitlement offer, oversubscribed by shareholders, to partly fund its acquisition of Johns Building Supplies in Western Australia.

TerraCom Limited has announced a partially underwritten renounceable entitlement offer aiming to raise approximately A$60 million to bolster its financial position amid ongoing coal price pressures. Key directors have committed to participate, while substantial shareholder Orbit Marketing stands ready to underwrite a significant portion of any shortfall.

TerraCom Limited confirms stable mining operations at Blair Athol despite logistical hurdles, while launching a A$60 million capital raise to bolster liquidity amid shipment timing challenges.

InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.